We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.20 | 0.01% | 1,705.40 | 1,705.20 | 1,705.60 | 1,709.60 | 1,699.40 | 1,701.60 | 1,248,138 | 13:50:13 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.23 | 70.1B |
Date | Subject | Author | Discuss |
---|---|---|---|
24/1/2019 15:49 | He's also behind top jobs for women | tradermichael | |
24/1/2019 15:19 | sterling will keep appreciating, thank god, brexit unlikely to happen now even the biggest brexit morons understand the damage but that isnt why the share price perma chronic, its the over priced pharma buyout the market doesnt like, capital destructive, plus chairman going, hes been pretty hopeless as the share price has done nothing under new ceo but at least it was him who pushed for break up. | porsche1945 | |
24/1/2019 14:08 | 1.20 to dollar? Maybe...but right now stg strengthening and GSK down. | zicopele | |
24/1/2019 12:29 | All overseas earners in the FTSE seem to be getting hit, as investors think pound to get stronger. Market is sleep walking to the 29th March. Bad deal or no deal, pound going lower. Shell, Gsk, Vod etc should bounce nicely as pound goes to 1.20 to the dollar. | montyhedge | |
24/1/2019 09:09 | IN @ 1468.92 ……. ;0) | tradermichael | |
24/1/2019 07:49 | Totally irrelevant, considering I hold GSK. | gbh2 | |
23/1/2019 20:05 | much better than aim stock | billionairepaddy | |
23/1/2019 19:57 | Dire share price performance atm ! | gbh2 | |
23/1/2019 10:54 | GlaxoSmithKline has a share of around 5% of the world's pharmaceutical market. The company employs around 99,300 people in over 100 countries. In 2010 they delivered 1.4 billion vaccine doses to 179 countries. As of today, it has a market capitalisation of £73.5 billion, the seventh largest on the London Stock Exchange. I'm staying put ….. at least till Emma's plan materialises ;0) P.S. I buy large quantities and sell on the swings to regularly gain small increments. That, plus the dividends covers my needs - and I always re-invest the returns. | tradermichael | |
23/1/2019 09:49 | When everything digested these will be higher, seems a crazy price. | montyhedge | |
23/1/2019 09:44 | GSK completes acquisition of TESARO, an oncology focused biopharmaceutical company GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that it has successfully completed the acquisition of TESARO, Inc. an oncology-focused company based in Waltham, Massachusetts, for an aggregate cash consideration of approximately $5.1 billion (GBP4.0 billion). The transaction, which was announced on 3 December 2018, significantly strengthens GSK's pharmaceutical business, accelerating the build of GSK's pipeline and commercial capability in oncology. That's not good news TM! They already had crippling debt levels and this big transaction, being for cash, must worsen that. It was known for some time but the news of completion is nothing to celebrate, quite the reverse. :~( What an appalling share GSK has been for long term growth investors. Glad I'm not one :~) | anhar | |
23/1/2019 09:02 | £1 = US$1.30 | tradermichael | |
22/1/2019 17:44 | Nice and steady 👍 | philanderer | |
22/1/2019 16:13 | GSK completes acquisition of TESARO, an oncology focused biopharmaceutical company GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that it has successfully completed the acquisition of TESARO, Inc. an oncology-focused company based in Waltham, Massachusetts, for an aggregate cash consideration of approximately $5.1 billion (GBP4.0 billion). The transaction, which was announced on 3 December 2018, significantly strengthens GSK's pharmaceutical business, accelerating the build of GSK's pipeline and commercial capability in oncology. | tradermichael | |
22/1/2019 13:05 | Thanks all | watfordhornet | |
22/1/2019 12:57 | Announcement date, Wednesday 6 February 2019. Ex-dividend date*, Thursday 21 February 2019. Record date, Friday 22 February 2019 Apparently. | wbecki | |
22/1/2019 12:57 | 2018 Q4 Ex-dividend date Thursday 21 February 2019 | tradermichael | |
22/1/2019 12:55 | When does this go ex divi for next qtr payment. Apologies if obvious but cannot find the date | watfordhornet | |
22/1/2019 12:21 | Can't get pass 1500p 1499p was the best so far. | montyhedge | |
22/1/2019 10:16 | SP is very unstable. | abdullla | |
22/1/2019 08:55 | 1500p resistance point, but if break through and hold at close, that's a great pivotal point broken. Then onwards and upwards. | montyhedge | |
21/1/2019 15:29 | RALLYYYYYYYYYY on this undiscovered stock .... Futura Medical (FUM)= Market cap 20 million /Cash 10.5 million / Potency Drug with 2 BILLION Market potential close to Phase 3 readout /CSD500 Condom approved in Europe and many Countries outside of Europa + more Approvals & Licensing deals coming / TPR100 (Topical Gel for Pain ) first approval expected next Quarter = POTENTIAL 10++ BAGGER GEM Futura Medical featured in Growth Company Investor recommendations 08 January 2019 CEO James Barder describes Futura as a medtech rather than biotech business. Its proprietary technology is DermaSys which delivers drugs rapidly through the skin and into the blood system. The lead product is MED2005 which is a topical gel for erectile dysfunction. The main advantage over Viagra is that it takes effect within five minutes, compared with over an hour for the famous blue pills. Which ensures key ingredients of spontaneity and mood can be retained while the treatment works. Research suggests a 20% market share could be possible, equating to sales of $560m in major western markets. In time an OTC version could more than double this. | bioking | |
21/1/2019 15:14 | I agree with TM, but Porsche is correct in saying that this share price is very disappointing. We talk about £16 or more but it is proving very difficult to stay above £15 just now. I believe EW has a fresh outlook, which is exciting and adventurous, but as yet with no evidence to give us real confidence. But I am sticking with GSK for now. | jadeticl3 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions